Trial reportCritical care (London, England)2026
Impact of renal vein doppler ultrasound-guided CVP titration in sepsis: a pilot randomized controlled trial.
Trial report in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo evaluate the feasibility and safety of a renal vein Doppler-guided central venous pressure (CVP) tritration protocol (RVD-CVP) in patients with sepsis, and to explore preliminary kidney-related and hemodynamic signals.
methodThis prospective, single-center, parallel-group pilot randomized controlled trial was conducted in an ICU between April and December 2023. Adults with sepsis and CVP monitoring were randomized 1:1 to RVD-CVP (renal vein Doppler assessments at 0, 6, 24, 48, and 72 h with prespecified CVP targets to maintain, lower, or defer) or usual care without renal vein Doppler guidance. The primary outcome was feasibility, defined as complete protocol delivery in the intervention group. Secondary outcomes were exploratory.
resultsOf 173 screened patients, 127 were randomized (63 intervention; 64 control). Complete protocol delivery was achieved in 63/63 intervention patients (100.0%; 95% CI, 94.3–100.0), and all scheduled renal vein Doppler assessments were completed (315/315, 100.0%). Safety-override deferrals occurred in 17/315 assessments (5.4%). AKI progression within 7 days occurred in 37/64 control vs. 27/63 intervention patients (57.0% vs. 43.0%; RR 0.74, 95% CI 0.52–1.06). The intervention group also had a lower rate of renal replacement therapy (RRT) initiation and a shorter duration of RRT compared to the control group (9.52% vs. 23.44%, RR 0.41, 95% CI 0.17–0.98, P = 0.035; 0.84 days vs. 2.39 days, P = 0.03). 28-day mortality was 7.9% vs. 12.5%. Additionally, vasopressor-free days at day 28 were higher (mean 22.12 vs. 18.84 days) and maximum norepinephrine dose was lower (mean 0.423 vs. 0.560 µg/kg/min) in the intervention group
conclusionIn this pilot randomized controlled trial, renal vein Doppler ultrasound–guided CVP titration was feasible and was associated with greater de-escalation and a lower fluid balance. Differences in AKI-related outcomes and renal replacement therapy use (including CRRT) were prespecified as exploratory secondary findings, and the trial was not powered to draw definitive conclusions on clinical outcomes. These signals should be interpreted cautiously and require confirmation in a larger, adequately powered randomized controlled trial. Clinical registration number: Register URL link: https://www.chictr.org.cn/ : Date:2023-12-12: Number: ChiCTR2300078565.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.